Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites

BACKGROUND AND OBJECTIVE: Tolvaptan, an oral vasopressin V2 receptor antagonist, has been widely used for the treatment of patients with cirrhosis and ascites. However, its efficacy in patients with renal dysfunction remains unknown. The objective of this study was to investigate the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Arase, Yoshitaka, Kagawa, Tatehiro, Tsuruya, Kota, Sato, Hirohiko, Teramura, Erika, Anzai, Kazuya, Hirose, Shunji, Deguchi, Ryuzo, Shiraishi, Koichi, Mine, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510826/
https://www.ncbi.nlm.nih.gov/pubmed/30284699
http://dx.doi.org/10.1007/s40261-018-0714-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510826/
https://www.ncbi.nlm.nih.gov/pubmed/30284699
http://dx.doi.org/10.1007/s40261-018-0714-5

Ejemplares similares